Lucid Medical Writing
 
   
 
Matt Lewis PhD
 
Publication acknowledgements


Data-driven patient clustering and differential clinical outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry.
Curtis JR, et al. Arthritis Care Res 2021;73:471–480
[Free full text]

Population pharmacodynamic model of neutrophil margination and tolerance to describe effect of sarilumab on absolute neutrophil count in patients with rheumatoid arthritis.
Kovalenko P, et al. CPT Pharmacometrics Syst Pharmacol 2020;9:405–416
[Free full text]

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.
Miller DH, et al. Ann Clin Transl Neurol 2018;5:346–356
[Free full text]

First human study of the investigational sedative and anesthetic drug AZD3043: a dose-escalation trial to assess the safety, pharmacokinetics, and efficacy of a 30-minute infusion in healthy male volunteers. Kalman S, et al. Anesth Analg 2015;121:885–893 [PubMed]

A bolus and bolus followed by infusion study of AZD3043, an investigational intravenous drug for sedation and anesthesia: safety and pharmacodynamics in healthy male and female volunteers. Norberg Å, et al. Anesth Analg 2015;121:894–903 [PubMed]

Tremelimumab: a review of development to date in solid tumors. Tarhini AA. Immunotherapy 2013;5:215–29 [PubMed]

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Kaye S, et al. Br J Cancer 2012;106:1728–34 [Free full text]

First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. Fujisaka Y, et al. Invest New Drugs 2012;31:108–14 [PubMed]

Pharmacological cardioversion of atrial fibrillation – a double-blind, randomized, placebo-controlled, multicentre, dose‑escalation study of AZD1305 given intravenously. Rσnaszιki A, et al. Europace 2011;13:1148–56 [Free full text]

QT response after a test dose and during maintenance therapy with AZD1305 in patients with atrial fibrillation: a double‑blind, randomized, placebo-controlled trial. Egstrup K, et al. Am J Cardiovasc Drugs 2011;11:199–208 [PubMed]

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple ascending dose phase I trial. Hannon RA, et al. J Bone Miner Res 2010;25:463–71 [PubMed]

A randomized invasive cardiac electrophysiology study of the combined ion channel blocker AZD1305 in patients after catheter ablation of atrial flutter. Toivonen L, et al. J Cardiovasc Pharmacol 2010;56:300–8 [PubMed]

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Boss DS, et al. Ann Oncol 2010;21:884–94
[Free full text]

Phase I safety, pharmacokinetics, and inhibition of Src activity study of saracatinib in patients with solid tumors.
Baselga J, et al. Clin Cancer Res 2010;16:4876–83
[Free full text]

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. James ND, et al. Eur Urol 2009;55:1112–1123 [PubMed]

Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Geller JC, et al. J Clin Pharmacol 2009;49:312–22 [PubMed]

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Green TP, et al. Mol Oncol 2009;3:248–61 [PubMed]

Zibotentan. James ND and Growcott JW. Drugs Fut 2009;34:624–34 [Journal]

[Poster] First report of the safety, tolerability, and pharmacokinetics of saracatinib (AZD0530) in Japanese patients with advanced solid tumours. Onozawa Y, et al. Eur J Cancer 2011;47(Suppl 1):S160